(via TheNewswire)

Vancouver, BC / TheNewswire / May 29, 2017 - SOLARVEST BIOENERGY INC. (TSX-V:SVS) ("Solarvest" or the "Company") is pleased to announce that it has signed a non-binding letter of intent ("LOI") with Sevo Nutraceuticals, Inc. ("Sevo") for exclusive North American rights to Perceptiv (R) , a nutraceutical formulation focused on the growing brain health market (the "License").

Solarvest will sublicense the rights from Sevo, which holds the worldwide, exclusive license from University of Massachusetts Lowell, who originally developed the product. Solarvest will be the North American partner in conjunction with Sevo's global marketing plan to grant regional sub-licensees in many international markets.

The LOI proposes that Solarvest will make a payment to Sevo of US$375,000 on closing of the License and will subsequently be responsible for paying a sliding scale royalty calculated on net revenue, subject to certain minimum payments. Solarvest would also be responsible for paying Sevo an additional US$500,000 per year for five years if certain FDA submitted evidence-based claim approvals are obtained. All terms of the agreement are subject to Solarvest's due diligence and negotiation of a definitive license agreement.

Perceptiv (R) is a patented nutraceutical clinically shown to protect against the normal cognitive decline associated with aging. Sevo completed a print-only test market of Perceptiv (R) in 2016, which produced sales of approximately $2,000,000. It has the distinction of being supported by seven published clinical trials and twenty years of research. Solarvest looks forward to taking Perceptiv (R) into widespread release in North America.

The LOI between the parties is non-binding, pending continued due diligence, board approvals, signing of a definitive license agreement and Solarvest successfully completing a Cdn$2,500,000 equity raise.

About Solarvest:

Solarvest is an algae technology company that owns numerous key patents. Our organic Omega3 patent is issued in Europe, UK, USA, Canada, Japan, India China, S. Korea, Hong Kong and Australia and is being defending in other significant countries. Its patented process produces the world's first organic DHA & EPA Omega-3 using algae. The company has been working with a contract manufacturer to achieve economic/commercial yields and is poised to supply the $25 billion dollar global Omega-3 market. The Solarvest system grows the algae under closely controlled conditions ensuring that the health products are produced without the environmental contaminants found in our oceans. In addition, organic certification provides our customers the assurance that the products are GMO free, sustainable and produced without chemicals. Since they are algae based the products are suitable for vegetarian and vegan diets. Solarvest's FDA licensed organic Omega-3 products offer the consumer a healthy and sustainable product choice.

About Sevo:

Sevo Nutraceuticals was established in Waltham, MA in 2012 to license and market science-based nutraceuticals.

For further information contact:

Gerri Greenham, Chief Executive Officer

Tel: 416 420 0947

Email: ggreenham@solarvest.ca

The TSX Venture Exchange has neither approved nor disapproved the contents of this news release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the Company's expectations and projections.

Copyright (c) 2017 TheNewswire - All rights reserved.